HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT
Clinical trials for HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT explained in plain language.
Never miss a new study
Get alerted when new HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT trials appear
Sign up with your email to follow new studies for HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a lower drug dose make stem cell transplants safer?
Disease control Recruiting nowThis trial investigates whether giving a reduced dose of the drug cyclophosphamide after a half-matched stem cell transplant can prevent graft-versus-host disease (GVHD) while causing fewer side effects. The standard dose often leads to infections and slow immune recovery. Resear…
Matched conditions: HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT
Phase: PHASE2 • Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could a cancer drug make stem cell transplants safer for sickle cell patients?
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to a standard stem cell transplant can prevent graft failure in children and young adults with severe sickle cell disease. Up to 24 participants will receive the drug during conditioning and be followed for two years after tran…
Matched conditions: HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT
Phase: PHASE1, PHASE2 • Sponsor: Arkansas Children's Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC